Clinical Trial Update: Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin [Phase 3]

View source ↗

Summary

Phase 3 trial update characterizing corneal epithelial changes in participants treated with belantamab mafodotin; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 3 | Status: TERMINATED | Results posted: 2023-12-13